Magnetic resonance spectroscopy

Journal of Neuro-Ophthalmology

Volumn 25, Issue 3, 2005, Pages 217-226

  Gujar, Sachin K ^a   Maheshwari, Sharad ^b   Björkman Burtscher, Isabella ^c   Sundgren, Pia C ^a,d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^c LUND UNIVERSITY   (Sweden)

^d Dept of Radiology UH B2 A209D ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE; LACTIC ACID; N ACETYLASPARTIC ACID;

BRAIN ABSCESS; BRAIN TUMOR; CANAVAN DISEASE; CANCER GRADING; CENTRAL NERVOUS SYSTEM DISEASE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION INJURY; REVIEW;

ASPARTIC ACID; BRAIN; CENTRAL NERVOUS SYSTEM DISEASES; CHOLINE; CREATINE; HUMANS; LACTIC ACID; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 24944562078     PISSN: 10708022     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wno.0000177307.21081.81     Document Type: Review

References (89)

1. Rubaek Danielsen E, Ross B (eds.). Magnetic resonance spectroscopy diagnosis of neurological disease. New York. Marcel Dekker, Inc. 1999.
2. Burtscher IM, Holtas S. Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 2001;13:560-7.
3. Novotny EJ, Jr., Fulbright RK, Pearl PL, et al. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol 2003;54:S25-31.
4. Valk J, Barkhof F, Scheltens P. Magnetic resonance in dementia. Berlin Heidelberg, Springer-Verlag, 2002.
5. Lenkinski RE, Schnall MD. MR Spectroscopy and the biochemical basis of neurological disease. In: Atlas SW, ed. Magnetic Resonance Imaging of the Head and Spine. New York: Raven, 1991:1099-1121.
6. Castillo M, Kwock L, Mukherji SK. Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 1996;17:1-15.
7. Maheshwari SR, Fatterpekar GM, Castillo M, Mukherji SK. Proton MR spectroscopy of the brain. Semin Ultrasound CT MR 2000;21: 434-51.
8. Barker PB. Fundamentals of MR Spectroscopy. In: Gillard JH, Waldman AD, Parker PB, eds. Clinical MR neuroimaging: diffusion, perfusion, and spectroscopy. Capetown: Cambridge University Press, 2005:1-17.
9. Burtscher IM, Holtas S. Proton magnetic resonance spectroscopy in brain tumors: clinical applications. Neuroradiology 2001;43:345-52.
10. Vigneron DB, Barkovich AJ, Noworolski SM, et al. Three-dimensional proton MR spectroscopic imaging of premature and term neonates. AJNR Am J Neuroradiol 2001;22:1424-33.
11. Wang ZJ, Zimmerman RA. Proton MR spectroscopy of pediatric metabolic disorders. NeuroImag Clin N Am 1998;8:781-807.
12. Zimmerman RA, Wang ZJ. The value of proton MR spectroscopy in pediatric metabolic brain disorders. AJNR Am J Neuroradiol 1997;18:1872-9.
13. Frahm J, Bruhn H, Gyngell ML, et al. Localized Proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med 1989;11:47-63.
14. Galanaud D, Le Fur Y, Nicoli F, et al. Regional metabolite levels of the normal posterior fossa studied by proton chemical shift imaging. MAGMA 2001;13:127-33.
15. Weybright P, Maly P, Gomez-Hassan D, Blaesing C, Sundgren PC. MR spectroscopy in the evaluation of recurrent contrast enhancing lesions in the posterior fossa after tumor treatment. Neuroradiol 2004;46:541-9.
16. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Mag Reson Med 1993;30:672-9.
17. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001;12: 141-52.
18. Smith JK, Londono A, Castillo M, Kwock L. Proton magnetic resonance spectroscopy of brain-stem lesions. Neuroradiology 2002; 44:825-9.
19. Kojic J, Robertson PL, Quint DJ, Martin DM, Pang Y, Sundgren PC. Brain glutamine by MRS in a patient with urea cycle disorder and coma. Pediatr Neurol 2005;32:143-6.
20. van der Knaap MS, van der Grond J, van Rijen PC, et al. Age dependent changes in localized proton and phosphorus MR spectroscopy of the brain. Radiology 1990;176:509-15.
21. Hetherington HP, Mason GF, Pan JW, et al. Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4.1T. Magn Reson Med 1994;32:565-71.
22. Tedeschi G, Bertolino A, Righini A, et al. Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 1995;45: 1384-91.
23. Kreis R, Ernst T, Ross BD. Development of the human brain: in vivo quantification of metabolite and water content by proton magnetic resonance spectroscopy. Magn Reson Med 1993;30:424-37.
24. Ala-Korpela M, Usenius JP, Keisala J, et al. Quantification of metabolites from single voxel in vivo 1H NMR data of normal human brain by means of a time-domain data analysis. MAGMA 1995;3: 129-36.
25. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized Proton MR spectra. Radiology 1993;187: 219-27.
26. Barker PB, Soher BJ, Blackband SJ, et al. Quantitation of proton NMR spectra of the human brain using tissue water as an internal concentration reference. NMR Biomed 1993;6:89-94.
27. Nelson SJ, McKnight TR, Henry RG. Characterization of untreated gliomas by magnetic resonance spectroscopic imaging. NeuroImag Clin N Am 2002;12:599-613.
28. Bruhn H, Frahm J, Gyngell MJ, et al. Noninvasive differentiation of tumors with the use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989;172: 541-8.
29. Pomper MG, Port JD. New techniques in MR imaging of brain tumors. Magn Reson Imag Clin N Am 2000;8:691-713.
30. Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002;44:371-81.
31. Herminghaus S, Dierks T, Pilatus U, et al. Determination of histopathological tumor grade in neuroepithelial brain tumors by using spectral pattern analysis of in vivo spectroscopic data. J Neurosurg 2003;98:74-81.
32. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604-12.
33. Burtscher IM, Holtas S. In vivo proton MR spectroscopy of untreated and treated brain abscesses. AJNR Am J Neuroradiol 1999;20: 1049-53.
34. Burtscher IM, Skagerberg G, Geijer B, et al. Proton MR Spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000;21:84-93.
35. Demaerel P. In vivo localized single-voxel proton magnetic resonance spectroscopy of intracranial tumors. Int J Neuroradiol 1997; 3:94-110.
36. Poptani H, Gupta RK, Roy R, et al. Characterization of intracranial mass lesions with in vivo proton MR spectroscopy. AJNR Am J Neuroradiol 1995;16:1593-60.
37. Poptani H, Gupta RK, Jain VK, et al. Cystic intracranial mass lesions: possible role of in vivo MR spectroscopy in its differential diagnosis. Magn Reson Imaging 1995;13:1019-29.
38. Björkman-Burtscher IM, Englund E, Skagerberg G. Proton MRS resonance at 2.05 ppm in mucin producing adenocarcinoma metastases in the brain. ISMRM 2004 Proceedings, Abstract 2080, pp 394.
39. Weybright P, Gomez Hassan D, Maly P, et al. Differentiation of tumor recurrence from treatment related changes using 2D-CSI MR Spectroscopy. AJR 2005. In press.
40. Movsas B, Li BS, Babb JS, et al. Quantifying radiation therapy-induced brain injury with whole brain proton MR spectroscopy: initial observations. Radiology 2001;221:327-31.
41. Wolinsky JS, Narayana PA. Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain. Curr Opin Neurol 2002;15:247-51.
42. van Walderveen MA, Barkhof F, Pouwels PJ, et al. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46: 79-87.
43. Rovaris M, Rocca MA, Filippi M. Magnetic resonance-based techniques for the study and management of multiple sclerosis. Br Med Bull 2003;65:133-44.
44. Fu L, Matthews PM, De Stefano N, et al. Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 1998;121: 103-1.
45. Sundgren PC, Dong Q, Gomez-Hassan D, et al. Diffusion tensor imaging of the brain: review of clinical applications. Neuroradiology 2004;46:339-50.
46. Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology 2001;56:1331-4.
47. Kovacs JA, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin N Am 1993;19:795-814.
48. Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematotus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994;37:369-75.
49. ACR ad hoc committee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
50. Lim MK, Suh CH, Kim HJ, et al. Systemic lupus erythematosus: brain magnetic resonance imaging and single-voxel hydrogen1 MR spectroscopy. Radiology 2000;217:43-9.
51. Axford JS, Howe FA, Heron C, Griffiths JR. Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann Rheum Dis 2001;60:106-11.
52. Sibbitt WL, Jr., Haseler LJ, Griffey RR, et al. Neurometabolism of active neuropsychiatric lupus determined with proton MR spectroscopy. AJNR Am J Neuroradiol 1997;18:1271-7.
53. Brooks WM, Sabet A, Sibbitt WL, Jr., et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997;24:2323-9.
54. Sundgren PC, Jennings J, Attwood TJ, et al. MRI and 2D-MR CSI spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus. Neuroradiology 2005. In press.
55. Harada M, Hisaoka S, Mori K, et al. Differences in water diffusion and lactate production in two different types of postinfectious encephalopathy. J Magn Reson Imaging 2000;11:559-63.
56. Bizzi A, Ulug AM, Crawford TO, et al. Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 2001;22:1125-30.
57. Moller HE, Vermathen P, Lentschig MG, et al. Metabolic characterization of AIDS dementia complex by spectroscopic imaging. J Magn Reson Imaging 1999;9:10-8.
58. Menon DK, Baudouin CJ, Tomlinson D, Hoyle C. Proton MR spectroscopy and imaging of the brain in AIDS: evidence of neuronal loss in regions that appear normal with imaging. J Comput Assist Tomogr 1990;14:882-5.
59. Laubenberger J, Haussinger D, Bayer S, et al. HIV-related metabolic abnormalities in the brain: depiction with proton MR spectroscopy with short echo times. Radiology 1996;199:805-10.
60. Chang L, Ernst T. MR spectroscopy and diffusion-weighted MR imaging in focal brain lesions in AIDS. Neuroimaging Clin N Am 1997;7:409-26.
61. Meyerhoff DJ, Bloomer C, Cardenas V, et al. Elevated subcortical choline metabolites cognitively and clinically asymptomatic patients in HIV+ patients. Neurology 1999;52:995-1003.
62. McConnell JR, Swindells S, Ong CS, et al. Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retroviruses 1994;10:977-82.
63. Chang L, Cornford ME, Chiang FL, et al. Radiologic-pathologic correlation. Cerebral toxoplasmosis and lymphoma in AIDS. AJNR Am J Neuroradiol 1995;16:1653-63.
64. Chinn RJ, Wilkinson ID, Hall-Craggs MA, et al. Toxoplasmosis and primary central nervous system lymphoma in HIV infection: diagnosis with MR spectroscopy. Radiology 1995;197: 649-54.
65. Cross JH, Gadian DG, Connelly A, Leonard JV. Proton magnetic resonance spectroscopy studies in lactic acidosis and mitochondrial disorders. J Inherit Metab Dis 1993;16:800-11.
66. Barkovich AJ, Good WV, Koch TK, Berg BO. Mitochondrial disorders: analysis of their clinical and imaging characteristics. AJNR Am J Neuroradiol 1993;14:1119-37.
67. Castillo M, Kwock L, Green C. MELAS syndrome: imaging and proton MR spectroscopic findings. AJNR Am J Neuroradiol 1995;16: 233-9.
68. Pouwels PJ, Kruse B, Korenke GC, et al. Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy. Neuropediatrics 1998;29:254-64.
69. Kruse B, Barker PB, van Zijl PC, et al. Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy. Ann Neurol 1994;36:595-608.
70. Zarifi MK, Tzika AA, Astrakas LG, et al. Magnetic resonance spectroscopy and magnetic resonance imaging findings in Krabbe's disease. J Child Neurol 2001;16:522-6.
71. Kruse B, Hanefeld F, Christen HJ, et al. Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo. J Neurol 1993; 241:68-74.
72. Battistini S, De Stefano N, Parlanti S, Federico A. Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. Funct Neurol 1991;6:177-80.
73. Pietz J, Kreis R, Schmidt H, et al. Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment. Radiology 1996;201:413-20.
74. Felber SR, Sperl W, Chemelli A, et al. Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol 1993;33:396-401.
75. Novotny EJ, Jr., Avison MJ, Hershkowitz N, et al. In vivo measurement of phenylalanine in human brain by proton magnetic resonance spectroscopy. Pediatr Res 1995;37:244-9.
76. Austin SJ, Connelly A, Gadian DG, et al. Localized 1H NMR spectroscopy in Canavan's disease: a report of two cases. Magn Reson Med 1991;19:439-45.
77. Marks HG, Caro PA, Wang ZY, et al. Use of computed tomography, magnetic resonance imaging, and localized 1H magnetic resonance spectroscopy in Canavan's disease: a case report. Ann Neurol 1991; 30:106-10.
78. Brockmann K, Dechent P, Meins M, et al. Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease. J Neurol 2003;250:300-6.
79. Cappellini M, Rapisardi G, Cioni ML, Fonda C. Acute hypoxic encephalopathy in the full-term newborn: correlation between magnetic resonance spectroscopy and neurological evaluation at short and long term. Radiol Med 2002;104:332-40.
80. Roelants-Van Rijn AM. Van der Grond J, De Vries LS, Groenendaal F. Value of (1)H-MRS using different echo times in neonates with cerebral hypoxia-ischemia. Pediatr Res 2001;49:356-62.
81. Connelly A, Jackson GD, Duncan JS, et al. Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology 1994;44:1411-7.
82. Kawaguchi S, Kamada K, Itamoto K, et al. Proton MR spectroscopy in patients with unilateral temporal lobe epilepsy. No To Shinkei 1995;47:43-8.
83. Castillo M, Smith JK, Kwock L. Proton MR spectroscopy in patients with acute temporal lobe seizures. AJNR Am J Neuroradiol 2001;22:152-7.
84. Brooks WM, Friedman SD, Gasparovic C. Magnetic resonance spectroscopy in traumatic brain injury. J Head Trauma Rehabil 2001; 16:149-64.
85. Friedman SD, Brooks WM, Jung RE, et al. Quantitative proton MRS predicts outcome after traumatic brain injury. Neurology 1999;52: 1384-91.
86. Garnett MR, Blamire AM, Rajagopalan B, et al. Evidence for cellular damage in normal-appearing white matter correlates with injury severity in patients following traumatic brain injury. A magnetic resonance spectroscopy study. Brain 2000;123:1403-9.
87. Garnett RM, Blamire AM, Corkill RG, et al. Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury. Brain 2000; 123: 2046-54.
88. Holshouser BA, Ashwal S, Luh GY, et al. Proton MR spectroscopy after acute central nervous system injury: outcome prediction in neonates, infants, and children. Radiology 1997;202:487-96.
89. Danielsen ER, Christensen PB, Arlien-Soborg P, Thomsen C. Axonal recovery after severe traumatic brain injury demonstrated in vivo by 1H MR spectroscopy. Neuroradiology 2003;45:722-4.